Greenstar Biosciences Announces M&A Focussed Strategic Additions to Its Executive Team and Corporate Update

In This Article:

Vancouver, British Columbia--(Newsfile Corp. - December 6, 2019) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company"), announces that it has engaged Invictus Accounting Group LLP ("Invictus") to provide CFO and strategic advisory services to the Company.

Mr. Brian Zasitko has been appointed the Company's Chief Financial Officer effective December 6, 2019. Mr. Zasitko replaces Mr. Alexander McAulay who has resigned his position of Chief Financial Officer.

Since 2012, Invictus has been providing a host of finance, advisory and accounting services, including financial reporting, tax compliance, assurance, deal structuring, and business advisory services, to both publicly listed and privately held companies. With their wealth of experience, they have led a variety of capital market initiatives and overseen numerous M&A transactions.

Mr. Zasitko is a senior consultant with Invictus, and has over 13 years of experience across a variety of private and public sector companies in the cannabis, agriculture, manufacturing, and utility industries. He has extensive experience in financial reporting and corporate governance, as well as in the capital markets. Previously, Mr. Zasitko was a manager at Ernst & Young LLP, where he obtained his CPA, CA designation.

"We are pleased to welcome Brian to our executive management team. His M&A and capital markets expertise will be integral as we pursue our expansion efforts. The Company is focused on pursuing M&A activity and the addition of Invictus and Brian are strategic steps the Company has taken to strengthen its management team with highly experienced M&A professionals," said Rahim Rajwani, Chief Executive Officer of GreenStar.

The Company also announces that it has entered into debt settlement agreements with two creditors for the settlement of debt in the aggregate amount of $66,000, which is to be settled through the issuance of an aggregate of 507,692 common shares in the capital of the Company (each, a "Share") at a deemed issue price of $0.13 per Share (the "Debt Settlement").

As a company controlled by the Company's Chief Financial Officer participated in the Debt Settlement, it is considered to be a "related party transaction" under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on exemptions from the formal valuation and minority approval requirements of MI 61-101, based on a determination that the securities of the Company are only listed on the CSE and that the fair market value of the Shares issued in connection with the Debt Settlement does not exceed $2,500,000 or 25% of the market capitalization of the Company. As the material change report disclosing the Debt Settlement is being filed less than 21 days before the transaction, there is a requirement under MI 61‐101 to explain why the shorter period was reasonable or necessary in the circumstances. In the view of the Company it was necessary to immediately close the Debt Settlement and therefore, such shorter period was reasonable in the circumstances.